AbbVie Inc
ABBV191.080USD
-1.339-0.70%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
337.50BValor de mercado
79.64P/L TTM
Mais detalhes de AbbVie Inc Empresa
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Informações da empresa
Código da empresaABBV
Nome da EmpresaAbbVie Inc
Data de listagemJan 02, 2013
Fundado em2012
CEOMr. Robert A. Michael, CPA
Número de funcionários55000
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 02
Endereço1 N Waukegan Rd
CidadeNORTH CHICAGO
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal60064
Telefone18479327900
Sitehttps://www.abbvie.com/
Código da empresaABBV
Data de listagemJan 02, 2013
Fundado em2012
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
51.91K
+2.37%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
51.91K
+2.37%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
Por RegiãoUSD
Nome
Receita
Proporção
United States
40.78B
72.39%
International
11.51B
20.42%
All other countries
3.03B
5.38%
Germany
1.47B
2.60%
Japan
1.12B
1.99%
Other
-1.57B
-2.79%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
Distribuição de ações
Atualizado em: sex, 21 de fev
Atualizado em: sex, 21 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.80%
BlackRock Institutional Trust Company, N.A.
5.15%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.17%
JP Morgan Asset Management
2.02%
Other
76.34%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.80%
BlackRock Institutional Trust Company, N.A.
5.15%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.17%
JP Morgan Asset Management
2.02%
Other
76.34%
Tipos de investidores
Investidores
Proporção
Investment Advisor
34.13%
Investment Advisor/Hedge Fund
29.68%
Research Firm
3.16%
Bank and Trust
2.22%
Pension Fund
2.19%
Sovereign Wealth Fund
1.54%
Hedge Fund
0.70%
Insurance Company
0.67%
Family Office
0.20%
Other
25.51%
Participação acionária institucional
Atualizado em: qui, 20 de fev
Atualizado em: qui, 20 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
5261
1.32B
74.47%
+9.10M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
2023Q1
4658
1.27B
71.97%
-18.58M
2022Q4
4628
1.27B
71.69%
-10.55M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
172.31M
9.74%
+1.45M
+0.85%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
90.08M
5.09%
+893.98K
+1.00%
Dec 31, 2024
State Street Global Advisors (US)
79.62M
4.5%
+553.55K
+0.70%
Dec 31, 2024
Geode Capital Management, L.L.C.
37.14M
2.1%
+983.89K
+2.72%
Dec 31, 2024
JP Morgan Asset Management
33.90M
1.92%
+881.83K
+2.67%
Dec 31, 2024
Capital Research Global Investors
33.98M
1.92%
+778.13K
+2.34%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
27.44M
1.55%
+3.60M
+15.10%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
25.10M
1.42%
+2.62M
+11.64%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.68M
1.28%
+844.34K
+3.87%
Dec 31, 2024
Fidelity Management & Research Company LLC
16.99M
0.96%
+3.92M
+30.04%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
First Trust Morningstar Dividend Leaders Index Fund
7.48%
First Trust NASDAQ Pharmaceuticals ETF
7.4%
Health Care Select Sector SPDR Fund
6.43%
Proshares Ultra Health Care
6.2%
iShares U.S. Healthcare ETF
6.17%
Goldman Sachs Future Health Care Equity ETF
6.1%
JPMorgan Healthcare Leaders ETF
5.85%
Fidelity MSCI Health Care Index ETF
5.55%
Direxion Daily Healthcare Bull 3X Shares
5.19%
VanEck Pharmaceutical ETF
5.06%
Ver Mais
First Trust Morningstar Dividend Leaders Index Fund
Proporção7.48%
First Trust NASDAQ Pharmaceuticals ETF
Proporção7.4%
Health Care Select Sector SPDR Fund
Proporção6.43%
Proshares Ultra Health Care
Proporção6.2%
iShares U.S. Healthcare ETF
Proporção6.17%
Goldman Sachs Future Health Care Equity ETF
Proporção6.1%
JPMorgan Healthcare Leaders ETF
Proporção5.85%
Fidelity MSCI Health Care Index ETF
Proporção5.55%
Direxion Daily Healthcare Bull 3X Shares
Proporção5.19%
VanEck Pharmaceutical ETF
Proporção5.06%
Dividendo
Um total de
48.58B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
